SynthesisWorld journal of gastroenterology2013
Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.
Synthesis in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis.BMC pregnancy and childbirth · 2022Pooled it
- Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review.Drugs · 2020Pooled it
- Safety of TNF-α inhibitors during IBD pregnancy: a systematic review.BMC medicine · 2013Pooled it
- A case series on TNF-α inhibitors for APS- induced high-risk pregnancies.Journal of clinical and translational science · 2025Article
- Mechanisms underlying the therapeutic effects ofFrontiers in molecular biosciences · 2024Article
- TNF-Expert reviews in molecular medicine · 2022Review
- Immune function in newborns withFrontiers in pediatrics · 2022Article
- Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.Gastroenterology · 2021Observational
- Pregnancy and medications in inflammatory bowel disease.Obstetric medicine · 2021Review
- Current Therapeutic Options in the Treatment of Rheumatoid Arthritis.Journal of clinical medicine · 2019Review
- New era of treatment with biologics in rheumatology - is it time to shift paradigms in treatment with biologics?Reumatologia · 2019Article
- Pregnancy and autoimmune connective tissue diseases.Best practice & research. Clinical rheumatology · 2016Review
- Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education.Canadian journal of gastroenterology & hepatology · 2016Article
- An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy.Open access rheumatology : research and reviews · 2016Review
- Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study.British journal of clinical pharmacology · 2015Observational
- Psoriasis in pregnancy: challenges and solutions.Psoriasis (Auckland, N.Z.) · 2015Review
- New approaches for managing preeclampsia: clues from clinical and basic research.Clinical therapeutics · 2014Review
- Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know.Therapeutic advances in musculoskeletal disease · 2014Review
- From conception to delivery: managing the pregnant inflammatory bowel disease patient.World journal of gastroenterology · 2014Review
- Connective tissue disease in pregnancy.Clinical medicine (London, England) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor-α inhibitors (anti-TNFs) are effective in the treatment of inflammatory bowel disease (IBD) recalcitrant to conventional medical therapy. As the peak incidence of IBD overlaps with the prime reproductive years, it is crucial to establish pharmacologic regimens for women of childbearing age that achieve effective disease control without posing significant fetal harm. A systematic literature review was performed to identify all human studies with birth outcomes data after maternal exposure to infliximab, adalimumab, or certolizumab pegol within 3 mo of conception or during any trimester of pregnancy. Live births, spontaneous abortions or stillbirths, preterm or premature births, low birth weight or small for gestational age infants, and congenital abnormalities were recorded. Fifty selected references identified 472 pregnancy exposures. The subsequent review includes general information regarding anti-TNF therapy in pregnancy followed by a summary of our findings. The benefits of biologic modalities in optimizing disease control during pregnancy must be weighed against the potential toxicity of drug exposure on the developing fetus. Although promising overall, there is insufficient evidence to prove absolute safety for use of anti-TNFs during pregnancy given the limitations of available data and lack of controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.